Table 1.
Clinical trials using mesenchymal stem cells (MSCs) as immunosuppressants
| Clinical trial | Disease | Cell type/source | Status | Sponsor | ClinicalTrials.gov identifier |
|---|---|---|---|---|---|
| Autologous mesenchymal stem cells from adipose tissue in patients with secondary progressive multiple sclerosis | Multiple sclerosis | Adipose tissue-derived autologous MSCs | Recruiting | Fundacion Progreso y Salud, Spain | NCT01056471 |
| Mesenchymal stem cell infusion as prevention for graft rejection and GVHD | GVHD | BM-derived autologous MSCs | Recruiting | University Hospital of Liege, Belgium | NCT00504803 |
| Mesenchymal stem cell transplantation in the treatment of chronic allograft nephropathy | Chronic allograft nephropathy | BM-derived autologous MSCs | Not yet recruiting | Fuzhou General Hospital, China | NCT00659620 |
| Mesenchymal stem cells and subclinical rejection | Renal transplantation | BM-derived allogenic MSCs | Not yet recruiting | Leiden University Medical Center, the Netherlands | NCT00734396 |
| Safety and efficacy study of umbilical cord blood-drived mesenchymal stem cells to promote engraftment of unrelated haematopoietic stem cell transplantation | GVHD | Human umbilical cord blood-derived MSCs | Not yet recruiting | Medipost Co. Ltd, Korea | NCT00823316 |
| Safety and efficacy study of allogenic mesenchymal stem cells to treat extensive chronic GVHD | Chronic GVHD | BM-derived allogenic MSCs | Not yet recruiting | Guangdong General Hospital, China | NCT00972660 |
| Evaluation of the role of mesenchymal stem cells in the treatment of GVHD | Steroid-resistant GVHD | BM-derived autologous MSCs | Recruiting | Christian Medical College, Vellore, India | NCT00314483 |
| Mesenchymal stem cell infusion as treatment for steroid-resistant acute GVHD or poor graft function | GVHD, poor graft function | BM-derived allogenic MSCs | Recruiting | University Hospital of Liege, Belgium | NCT00603330 |
| Safety and efficacy study of adult human mesenchymal stem cells to treat acute GVHD | GVHD | BM-derived allogenic MSC (prochymal) | Completed | Osiris Therapeutics, USA | NCT00136903 |
| Treatment of refractory (acute or chronic) GVHD by the infusion of expanded in-vitro allogenic mesenchymal stem cell | GVHD | BM-derived allogenic MSCs | Recruiting | University of Salamanca, Spain | NCT00447460 |
| Mesenchymal stem cells for treatment of amyotrophic lateral sclerosis | Amyotrophic lateral sclerosis | Adipose tissue-derived autologous MSCs | Not yet recruiting | Mayo Clinic, USA | NCT01142856 |
| Mesenchymal stem cells under basiliximab/low-dose RATG to induce renal transplant tolerance | Kidney transplant | BM-derived autologous MSCs | Recruiting | Mario Negri Institute for Pharmacological Research, Italy | NCT00752479 |
| Mesenchymal stem cells transplantation for refractory systemic lupus erythematosus | Refractory systemic lupus erythematosus | BM-derived allogenic MSCs | Recruiting | Nanjing Medical University, China | NCT00698191 |
| Efficacy and safety of adult human mesenchymal stem cells to treat patients who have failed to respond to steroid treatment for acute GVHD | GVHD | BM-derived allogenic MSC (prochymal) | Completed | Osiris Therapeutics, USA | NCT00366145 |
| Donor mesenchymal stem cell infusion in treating patients with acute or chronic GVHD after undergoing a donor stem cell transplant | GVHD | BM-derived allogenic MSCs | Not yet recruiting | Case Comprehensive Cancer Center | NCT00361049 |
| Safety and efficacy of prochymal for the salvage of treatment-refractory acute GVHD patients | GVHD | BM-derived allogenic MSCs | Completed | Osiris Therapeutics, USA | NCT00284986 |
| Safety and efficacy of human mesenchymal stem cells for treatment of liver failure | Liver failure | Human umbilical cord-derived MSCs | Recruiting | Beijing 302 Hospital, China | NCT01218464 |
| Umbilical cord mesenchymal stem cells for immune reconstitution in HIV-infected patients | HIV | Human umbilical cord-derived MSCs | Recruiting | Beijing 302 Hospital, China | NCT01213186 |
BM: bone marrow; GVHD: graft-versus-host disease; HIV: human immunodeficiency virus; RATG: rabbit anti-human thymocyte globulin.